flurazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1218 17617-23-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flurazepam
  • stauroderm
  • flurazepam hydrochloride
  • flurazepam HCl
A benzodiazepine derivative used mainly as a hypnotic.
  • Molecular weight: 387.88
  • Formula: C21H23ClFN3O
  • CLOGP: 4.21
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 35.91
  • ALOGS: -4.59
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 500 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
April 7, 1970 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 690.75 45.59 160 2180 22004 63464678
Drug abuse 408.96 45.59 137 2203 72381 63414301
Intentional self-injury 246.27 45.59 73 2267 25614 63461068
Intentional overdose 211.36 45.59 85 2255 74067 63412615
Suicide attempt 198.65 45.59 77 2263 60841 63425841
Bradyphrenia 127.68 45.59 33 2307 6947 63479735
Toxicity to various agents 110.66 45.59 83 2257 247167 63239515
Substance abuse 74.79 45.59 20 2320 4787 63481895
Somnolence 56.31 45.59 49 2291 178636 63308046
Hypokinesia 50.19 45.59 19 2321 13917 63472765
Coma 48.66 45.59 30 2310 64334 63422348
Mydriasis 45.60 45.59 17 2323 11939 63474743

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 161.19 38.45 44 1185 12092 34943610
Drug abuse 145.35 38.45 70 1159 99026 34856676
Intentional self-injury 86.41 38.45 28 1201 13743 34941959
Psychomotor hyperactivity 70.38 38.45 22 1207 9600 34946102
Feelings of worthlessness 57.98 38.45 10 1219 309 34955393
Abulia 51.68 38.45 10 1219 590 34955112
Suicide attempt 46.21 38.45 24 1205 39092 34916610
Obsessive-compulsive disorder 46.06 38.45 14 1215 5550 34950152
Restless legs syndrome 40.47 38.45 14 1215 8340 34947362

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 797.08 36.75 200 3226 32810 79708152
Drug abuse 493.58 36.75 203 3223 162488 79578474
Intentional self-injury 338.84 36.75 102 3324 32317 79708645
Suicide attempt 185.98 36.75 84 3342 82848 79658114
Intentional overdose 181.20 36.75 89 3337 105871 79635091
Bradyphrenia 157.68 36.75 44 3382 10596 79730366
Toxicity to various agents 93.46 36.75 102 3324 421438 79319524
Psychomotor hyperactivity 57.35 36.75 23 3403 16826 79724136
Substance abuse 56.29 36.75 20 3406 10506 79730456
Hypokinesia 54.60 36.75 23 3403 19037 79721925
Feelings of worthlessness 50.48 36.75 10 3416 542 79740420
Drug interaction 49.59 36.75 74 3352 415109 79325853
Somnolence 46.19 36.75 54 3372 238927 79502035
Bradykinesia 45.75 36.75 16 3410 8027 79732935
Abulia 44.36 36.75 10 3416 1010 79739952
Obsessive-compulsive disorder 42.38 36.75 14 3412 5913 79735049
Coma 40.57 36.75 34 3392 100615 79640347

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD01 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:35717 hypnotics
CHEBI has role CHEBI:91016 GABAA receptor agonists
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175694 Benzodiazepine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Disorder of lung contraindication 19829001 DOID:850
Borderline personality disorder contraindication 20010003 DOID:10930
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Decreased respiratory function contraindication 80954004
Kidney disease contraindication 90708001 DOID:557
Hypoalbuminemia contraindication 119247004
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Pregnancy, function contraindication 289908002
Coma contraindication 371632003
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004
Behavioral Disorders contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.24 Basic
pKa2 1.92 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR IC50 8.10 WOMBAT-PK CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.22 WOMBAT-PK

External reference:

IDSource
4019763 VUID
N0000147854 NUI
D00329 KEGG_DRUG
1172-18-5 SECONDARY_CAS_RN
4017827 VANDF
4019763 VANDF
C0016375 UMLSCUI
CHEBI:5128 CHEBI
FL7 PDB_CHEM_ID
CHEMBL3989724 ChEMBL_ID
CHEMBL968 ChEMBL_ID
DB00690 DRUGBANK_ID
D005479 MESH_DESCRIPTOR_UI
3393 PUBCHEM_CID
7188 IUPHAR_LIGAND_ID
2551 INN_ID
IHP475989U UNII
4501 RXNORM
4752 MMSL
70 MMSL
d00238 MMSL
001463 NDDF
004584 NDDF
19403009 SNOMEDCT_US
27928002 SNOMEDCT_US
387109000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4415 CAPSULE 15 mg ORAL ANDA 27 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4415 CAPSULE 15 mg ORAL ANDA 27 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4430 CAPSULE 30 mg ORAL ANDA 27 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-4430 CAPSULE 30 mg ORAL ANDA 27 sections
Flurazepam HUMAN PRESCRIPTION DRUG LABEL 1 21695-363 CAPSULE 30 mg ORAL ANDA 19 sections
Flurazepam HUMAN PRESCRIPTION DRUG LABEL 1 52959-236 CAPSULE 30 mg ORAL ANDA 19 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0092 CAPSULE 15 mg ORAL ANDA 14 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-0093 CAPSULE 30 mg ORAL ANDA 14 sections
Flurazepam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 55289-038 CAPSULE 30 mg ORAL ANDA 26 sections